Veracyte’s ASCO Urology Data And TrueMRD Launch Test Investor Patience

Simply Wall St.02-26 21:36

Veracyte, ticker NasdaqGM:VCYT, plans to present more than 15 abstracts from its urology portfolio at the 2026 ASCO Genitourinary Cancers Symposium. The company is preparing to launch its TrueMRD test...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614476910?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-26 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614476910","market":"us","top_or_hot":-1,"title":"Veracyte’s ASCO Urology Data And TrueMRD Launch Test Investor Patience","media":"Simply Wall St.","content":"<div>\n<p>Veracyte, ticker NasdaqGM:VCYT, plans to present more than 15 abstracts from its urology portfolio at the 2026 ASCO Genitourinary Cancers Symposium. The company is preparing to launch its TrueMRD test...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracytes-asco-urology-data-and-truemrd-launch-test-investor\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veracyte’s ASCO Urology Data And TrueMRD Launch Test Investor Patience</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeracyte’s ASCO Urology Data And TrueMRD Launch Test Investor Patience\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracytes-asco-urology-data-and-truemrd-launch-test-investor><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Veracyte, ticker NasdaqGM:VCYT, plans to present more than 15 abstracts from its urology portfolio at the 2026 ASCO Genitourinary Cancers Symposium. The company is preparing to launch its TrueMRD test...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracytes-asco-urology-data-and-truemrd-launch-test-investor\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracytes-asco-urology-data-and-truemrd-launch-test-investor","article_id":"2614476910","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracytes-asco-urology-data-and-truemrd-launch-test-investor","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614476910","pubTimestamp":1772112990,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Veracyte, ticker NasdaqGM:VCYT, plans to present more than 15 abstracts from its urology portfolio at the 2026 ASCO Genitourinary Cancers Symposium.\nThe company is preparing to launch its TrueMRD test for muscle invasive bladder cancer and continues to build out its broader genomic testing offerings.\n\nVeracyte enters this news cycle with its shares at $35.72 and a mixed return profile, including a 50.7% gain over three years alongside a 15.7% decline year to date and a 12.0% decline over the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc","BK4139":"生物科技"},"translate_title":"Veracyte的ASCO泌尿学数据和TrueMRD发布测试投资者的耐心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1.5},"content_text":"Veracyte, ticker NasdaqGM:VCYT, plans to present more than 15 abstracts from its urology portfolio at the 2026 ASCO Genitourinary Cancers Symposium. The company is preparing to launch its TrueMRD test for muscle invasive bladder cancer and continues to build out its broader genomic testing offerings.  Veracyte enters this news cycle with its shares at $35.72 and a mixed return profile, including a 50.7% gain over three years alongside a 15.7% decline year to date and a 12.0% decline over the past month. For investors tracking diagnostics names, this combination of recent share price pressure and longer term compounding can highlight why fresh clinical data and product launches may be important signals. The upcoming TrueMRD launch and expanded urology data set indicate active product pipeline work that could influence how the business evolves from here. As you assess NasdaqGM:VCYT, this type of clinical and commercial progress may matter as much as the usual quarterly numbers, particularly for investors focused on cancer testing platforms and their role in patient care. Stay updated on the most important news stories for Veracyte by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Veracyte. NasdaqGM:VCYT Earnings & Revenue Growth as at Feb 2026 4 things going right for Veracyte that this headline doesn't cover. AdvertisementQuick Assessment  ✅ Price vs Analyst Target: At US$35.72 versus an analyst target of US$47.67, the price sits about 25% below consensus expectations. ✅ Simply Wall St Valuation: Simply Wall St currently flags Veracyte as trading around 36.8% below its estimated fair value. ❌ Recent Momentum: The 30 day return of roughly 12% decline shows recent selling pressure despite the upcoming ASCO data and TrueMRD launch.  There is only one way to know the right time to buy, sell or hold Veracyte. Head to Simply Wall St's\ncompany report for the latest analysis of Veracyte's Fair Value.. Key Considerations  📊 The ASCO genitourinary presentations and TrueMRD launch keep the urology franchise in focus, which matters for how you frame Veracyte as a cancer testing platform play. 📊 Keep an eye on adoption metrics for TrueMRD, urology test volumes and how these feed into revenue, margins and the current P/E of about 93x. ⚠️ One flagged risk is that large one off items affect reported earnings quality, so you may want to separate recurring performance from non recurring items when reviewing results tied to this news.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete Veracyte analysis. Alternatively, you can check out the\ncommunity page for Veracyte to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614476910","isCrawlerRequest":true}